Bjarni A. Agnarsson

Reykjavik, Iceland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.

Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 14, 2026

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Journal: Leukemia

Published: April 22, 2026

Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study.

Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study.

Journal: Blood cancer journal

Published: October 08, 2025

Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.

Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.

Journal: Leukemia

Published: June 26, 2025

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance.

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance.

Journal: JAMA oncology

Published: May 29, 2025

Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS.

Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS.

Journal: Blood advances

Published: May 28, 2025

Skin-Homing Potential of Peripheral Immune Cells From Psoriasis Patients and the Effects of LL-37 on Their Secretion of Chemokines During Psoriasis-Mimicking Stimulation.

Skin-Homing Potential of Peripheral Immune Cells From Psoriasis Patients and the Effects of LL-37 on Their Secretion of Chemokines During Psoriasis-Mimicking Stimulation.

Journal: Scandinavian journal of immunology

Published: February 21, 2025

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study.

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study.

Journal: Blood

Published: September 27, 2024

Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population-based screening study.

Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population-based screening study.

Journal: British journal of haematology

Published: September 19, 2024

The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study.

The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study.

Journal: Blood cancer journal

Published: August 27, 2024

Analysis of smoldering multiple myeloma according to the target of the monoclonal immunoglobulin of patients.

Analysis of smoldering multiple myeloma according to the target of the monoclonal immunoglobulin of patients.

Journal: HemaSphere

Published: August 04, 2024

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

Journal: The British journal of dermatology

Published: July 12, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026